Anti-IGF1R/ CD221/ IGFIR monoclonal antibody

Anti-IGF1R/ CD221/ IGFIR antibody for FACS & in-vivo assay

Target products collectionGo to IGF1R/IGF1R products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T48069-Ab-1/ GM-Tg-hg-T48069-Ab-2Anti-Human IGF1R monoclonal antibodyHuman
GM-Tg-rg-T48069-Ab-1/ GM-Tg-rg-T48069-Ab-2Anti-Rat IGF1R monoclonal antibodyRat
GM-Tg-mg-T48069-Ab-1/ GM-Tg-mg-T48069-Ab-2Anti-Mouse IGF1R monoclonal antibodyMouse
GM-Tg-cynog-T48069-Ab-1/ GM-Tg-cynog-T48069-Ab-2Anti-Cynomolgus/ Rhesus macaque IGF1R monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T48069-Ab-1/ GM-Tg-felg-T48069-Ab-2Anti-Feline IGF1R monoclonal antibodyFeline
GM-Tg-cang-T48069-Ab-1/ GM-Tg-cang-T48069-Ab-2Anti-Canine IGF1R monoclonal antibodyCanine
GM-Tg-bovg-T48069-Ab-1/ GM-Tg-bovg-T48069-Ab-2Anti-Bovine IGF1R monoclonal antibodyBovine
GM-Tg-equg-T48069-Ab-1/ GM-Tg-equg-T48069-Ab-2Anti-Equine IGF1R monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T48069-Ab-1/ GM-Tg-hg-T48069-Ab-2; GM-Tg-rg-T48069-Ab-1/ GM-Tg-rg-T48069-Ab-2;
GM-Tg-mg-T48069-Ab-1/ GM-Tg-mg-T48069-Ab-2; GM-Tg-cynog-T48069-Ab-1/ GM-Tg-cynog-T48069-Ab-2;
GM-Tg-felg-T48069-Ab-1/ GM-Tg-felg-T48069-Ab-2; GM-Tg-cang-T48069-Ab-1/ GM-Tg-cang-T48069-Ab-2;
GM-Tg-bovg-T48069-Ab-1/ GM-Tg-bovg-T48069-Ab-2; GM-Tg-equg-T48069-Ab-1/ GM-Tg-equg-T48069-Ab-2
Products NameAnti-IGF1R monoclonal antibody
Formatmab
Target NameIGF1R
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IGF1R benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-231Pre-Made Ganitumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
    BiosimilarGMP-Bios-ab-213Pre-Made Figitumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
    BiosimilarGMP-Bios-ab-282Pre-Made Istiratumab biosimilar, Bispecific Mixed mAb and scFv, Anti-IGF1R;ERBB3/Erbb-3 Antibody: Anti-IGFR/CD221/IGFIR/JTK13;FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-c-erbB3/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    BiosimilarGMP-Bios-ab-321Pre-Made Lonigutamab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
    BiosimilarGMP-Bios-ab-489Pre-Made Robatumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
    BiosimilarGMP-Bios-ab-564Pre-Made Teprotumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
    BiosimilarGMP-Bios-INN-897Pre-Made Lonigutamab Ugodotin Biosimilar, Whole Mab Adc, Anti-Igf1R Antibody: Anti-CD221/IGFIR/IGFR/JTK13 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-108Pre-Made Cixutumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
    BiosimilarGMP-Bios-ab-131Pre-Made Dalotuzumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species IGF1R/ CD221/ IGFIR VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T48069-Ag-1Insulin-like Growth Factor-I (IGF1R) protein


    Target information

    Target IDGM-T48069
    Target NameIGF1R
    Gene ID3480,16001,25718,708227,442951,100500937,281848,100055698
    Gene Symbol and SynonymsA330103N21Rik,CD221,D930020L01,hyft,IGF-1 receptor,IGF-1R,IGF1R,IGFIR,IGFIRC,IGFR,Igfr1,JTK13
    Uniprot AccessionP08069,P24062,Q05688
    Uniprot Entry NameIGF1R_HUMAN,IGF1R_RAT,IGF1R_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000140443
    Target ClassificationCheckpoint-Immuno Oncology, Kinase, Tumor-associated antigen (TAA)

    The target: IGF1R, gene name: IGF1R, also named as CD221, IGFIR, IGFR, JTK13. This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.